The Power of Citizen-Generated Health Data – a Business Review Life Science Podcast

The Power of Citizen-Generated Health Data – a Business Review Life Science Podcast

Copenhagen, Denmark 

Monsenso is happy to announce that our CEO, Thomas Lethenborg, recently participated in the Business Review Life Science podcast, joining a compelling panel discussion on the transformative potential of real-world patient-reported data.

The episode, titled “Borgernes egne sundhedsdata” (“Citizen-Generated Health Data”), will be aired on August 11th and features key voices from the ongoing Phase V innovation project.

Hosted by Heidi Bendtsen Nielsen, the podcast explores how personal health data – such as information collected via smartphones, blood pressure monitors, or smartwatches – can be used to enhance treatment outcomes, support prevention, and relieve pressure on healthcare systems.

Thomas Lethenborg was joined by:

  • Frederik Knud Nielsen, Healthcare Partnership Director at Novartis
  • Frederik Mølgaard Thayssen, Principal Project Manager at the Alexandra Institute

Together, the panel addressed several timely and critical questions:

  • What opportunities do Danes have today to collect and contribute their own health data?
  • How can these data be validated and effectively integrated into healthcare practices?
  • What barriers – regulatory, ethical, or technical – still need to be overcome?
  • How can public-private collaborations, like Phase V, unlock the full potential of data-driven healthcare?

“At Monsenso, we see real-world data as a key enabler of more personalised, preventive, and efficient healthcare”, said Thomas Lethenborg. “This podcast gave us a great platform to highlight not only the technological possibilities but also the importance of patient involvement and responsible data use.”

The discussion also emphasised the need for stronger political commitment to support personalised, data-driven innovation in healthcare and showcased examples of successful collaborations between industry and the public sector – including the Phase V initiative.

Listeners can access the full episode (in Danish) on the Business Review Life Science platform.


To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Monsenso supports UK research on treatment-resistant depression

Monsenso supports UK research on treatment-resistant depression

Copenhagen, Denmark

Monsenso delivers digital research platform for groundbreaking UK project on treatment-resistant depression.

Monsenso A/S is proud to announce its strategic role as the digital technology partner for the DECODE project in the United Kingdom. The initiative, led by the University of Birmingham, in collaboration with the Mental Health Mission Midlands Translational Centre, Birmingham and Solihull NHS Foundation Trust, and Nottinghamshire Healthcare NHS Foundation Trust, is focused on transforming clinical research and care for patients with treatment-resistant depression (TRD).

As part of the project, Monsenso’s digital platform will enable stratified recruitment, remote data collection, and standardised clinical endpoint measurement across multiple NHS sites — laying the groundwork for improved precision in depression research and future interventions.

Addressing a Critical Public Health Challenge

Treatment-resistant depression (TRD) affects almost half of patients diagnosed with major depressive disorder meaning they do not respond to two or more oral antidepressants, and TRD is associated with poorer outcomes, including high comorbidity, suicidality, and economic burden. 

The DECODE project aims to build a digitally enabled recruitment and monitoring infrastructure to better identify, understand, and ultimately treat this complex condition.

Recruitment is expected to begin in Q3 2025, with Monsenso’s platform playing a pivotal role in data collection and patient stratification.

Quote from Monsenso CEO

We are honoured to support such an important national initiative addressing one of the most challenging areas in mental health. Monsenso’s platform is designed to help healthcare providers and researchers make better, data-driven decisions through real-time digital monitoring and standardised assessments,” said Thomas Lethenborg, CEO of Monsenso.

This project reaffirms our strategic positioning as a trusted partner in supporting decentralised, real-world data studies across Europe with healthcare, academic institutions and pharmaceuticals.

Strategic Importance for Monsenso

  • Expansion into the UK: Strengthens Monsenso’s footprint within the UK healthcare ecosystem, particularly within the NHS and leading academic partners.
  • Scalable digital, decentralised research model: Demonstrates the scalability and flexibility of Monsenso’s platform for decentralised multi-site health research.
  • Expansion possibilities: If successful, the DECODE project has potential to pave the way for geographic expansion and follow-on precision-medicine studies.
  • Validation of product-market fit: Reinforces Monsenso’s role in delivering regulated, patient-centric digital tools that meet the complex needs of decentralised, real-world studies in psychiatric conditions and beyond.

Academic and Clinical Endorsement

Professor Steven Marwaha, Co-director of the Midlands Mental Health Mission and Professor at the University of Birmingham, stated:

This partnership with Monsenso enables us to streamline and enhance the way we recruit patients and assess outcomes. By integrating continuous data collection, digital phenotyping tools and standardising clinical endpoints, we can accelerate our understanding of treatment-resistant depression and drive more precise and personalised future interventions.


Click the button below for more information about the Monsenso solution.

Welcoming the NHS 10-Year Plan

Welcoming the NHS 10-Year Plan

Copenhagen, Denmark 

On July 3rd 2025, the UK Government published Fit for the Future: 10 Year Health Plan for England, outlining a bold, transformative vision to make the NHS sustainable, equitable, and technology-led for the next decade and beyond.

This plan hinges on three radical shifts:

  1. From hospital to community
  2. From analogue to digital
  3. From sickness to prevention

It emphasizes empowering patients, deploying predictive and preventive care, embracing wearables and AI, integrating care teams locally, and making NHS staff more effective and supported.

Monsenso celebrates these ambitions, and stands ready to support the NHS in delivering them.

How Monsenso Aligns with the NHS Vision

Hospital → Community: Local, continuous, personalised mental health support

The NHS aims to shift care into neighbourhood health centres and patients’ homes, creating continuous, integrated care pathways.

Monsenso’s digital health platform enables precisely this shift into remote patient monitoring. By combining self-reported symptom data with wearable sensor data, our system allows clinicians to monitor mental health remotely, detect early signs of deterioration, and intervene proactively, without waiting for hospital referrals.

Analogue → Digital: Empowered patients and data-driven care 

With the NHS committed to digital transformation, turning the NHS App into a full “front door”, Monsenso offers a complementary digital health tool that seamlessly integrates into clinicians’ workflows while putting patients in control of their day-to-day mental health management .

Our mobile apps support:

  • Electronic patient-reported outcomes (e-PROs)
  • Medication and appointment reminders
  • Psychoeducational content and self-help tools
  • Secure two-way messaging between patients and care teams

Clinicians gain access to actionable dashboards, analytics and predictive risk alerts; all in the cloud, accessible anytime, anywhere.

Sickness → Prevention: Early detection, digital prevention, value-based care

The NHS plan emphasises predictive care, with wearables becoming standard, and incentives for preventive interventions & value-based outcomes .

Monsenso supports predictive analytics and mood forecasting, drawing on real-world behavioural data to flag rising risk and support earlier intervention before crisis points. Campaigns like the ECoWeB CBT-based app trials – built on Monsenso’s platform – have demonstrated that sustained self-help interventions can prevent depression onset in high-risk youth across several countries. This aligns with the NHS’s focus on prevention, mental wellbeing in young people, and cost-effective scaling.

Supporting workforce, transparency & innovation

The NHS wants a workforce empowered through digital tools, and more transparency using patient-reported outcome measures and performance data. By providing clinicians with real-time insights into engagement, adherence, symptoms and outcomes, Monsenso reduces administrative burden, enables triage based on clinical risk, and supports shared decision-making with patients.

As a CE and UKCA-marked medical device, certified to ISO 27001, ISO 13485 and Cyber Essentials, Monsenso meets the UK and EU regulatory and digital compliance standards, and is ready to integrate within NHS quality, safety, and innovation frameworks.

Key Benefits for NHS Mental Health Services

NHS Priority Area How Monsenso Helps
Community-based care Enables remote monitoring, blended care and integration across primary, secondary and community settings
Digital access  A digital companion that could be aligned with NHS App ‘HealthStore’ pathways and services
Preventive mental health Predictive analytics, self-help interventions, early risk detection, and prevention of relapse or crisis
Patient empowerment & equity Inclusive tools for self-management, carers and diverse populations; scalable across regions
Workforce productivity Streamlines patient review, prioritises high-risk cases, reduces admin burden, freeing clinicians for care.

 

Championing Change with Monsenso

At Monsenso, our mission is to make mental healthcare more predictive, equitable, person-centred, and scalable – perfectly aligned with the NHS 10-Year Plan. Our digital health platform is already in use in multiple countries, supporting thousands of individuals living with conditions such as depression, bipolar disorder, anxiety, schizophrenia, and addiction. With high adherence rates and robust real-world evidence from research partnerships, we know digital tools can work at scale.

We’re ready to collaborate with NHS England, integrated care boards, neighbourhood health centres and mental health providers to deliver against key NHS targets – especially for youth mental health, the expansion of mental health in primary care and remote psychological support.

Looking Ahead

As the NHS embarks on its most transformative decade, Monsenso is poised to partner where technology, data-driven care and human-centred health practice converge. We look forward to supporting the NHS to make mental and somatic health support more accessible, effective and forward-looking – together.


To learn more or explore a pilot or integration, book a demo or get in touch via our website.

 

Denmark Completes 10-Year Plan for Psychiatry – Strengthening Mental Health for the Future

Denmark Completes 10-Year Plan for Psychiatry – Strengthening Mental Health for the Future

Copenhagen, Denmark 

The Danish Government has presented the final part of its comprehensive 10-year plan for psychiatry, a long-term initiative designed to secure better mental health services across the country. The new proposal builds on several years of investments and reforms and represents a turning point in how psychiatric care is organised and delivered in Denmark.

The plan’s ambition is clear: to ensure that all individuals living with mental health challenges can access timely, effective, and high-quality treatment, while also receiving support that enables them to thrive in everyday life.

Key elements of the plan include:

  • Earlier intervention and prevention: Strengthening outreach and ensuring that signs of mental illness are detected and addressed sooner.

  • More treatment capacity: Expanding resources in both child & adolescent psychiatry and adult psychiatry to meet rising demand.

  • Cross-sector collaboration: Closer integration between psychiatry, primary care, social services, and education, ensuring patients receive coordinated support across systems.

  • Focus on recovery and everyday life: Shifting attention from acute treatment alone to also supporting long-term recovery, rehabilitation, and reintegration into school, work, and community.

  • Better access and reduced inequality: Targeting efforts to ensure equal access to psychiatric services regardless of geography, social background, or economic status.

The plan underlines that psychiatry is not only a medical challenge but a societal one. Mental health must be supported not just in hospitals and clinics, but also in schools, workplaces, families, and communities.

How Monsenso Contributes

At Monsenso, we strongly welcome the government’s continued prioritisation of psychiatry. The principles set out in the 10-year plan align closely with our mission to empower individuals, clinicians, and healthcare systems through digital innovation.

Our digital health platform is already supporting psychiatric care across Denmark and internationally, and can help realise several of the government’s ambitions:

  • Early detection and intervention
    By capturing real-time patient-reported outcomes and digital biomarkers, the Monsenso solution helps clinicians identify changes in symptoms at an earlier stage. This enables timely support and prevents conditions from escalating.

  • Strengthening cross-sector collaboration
    The platform facilitates secure data sharing and communication between patients, relatives, and care teams across healthcare sectors. This ensures that information follows the patient, promoting coordinated treatment pathways.

  • Supporting recovery in everyday life
    Our mobile app empowers individuals to actively engage in their own treatment, track progress, and access coping strategies directly from home. This helps extend care beyond the clinic, improving continuity and supporting long-term recovery.

  • Promoting equality and accessibility
    Digital tools can help reduce geographic and social disparities by making care more accessible, particularly for those in remote areas or with limited ability to attend frequent in-person consultations.

    Building the Psychiatry of the Future

    The Danish Government’s 10-year plan for psychiatry represents a historic opportunity to strengthen mental health services for generations to come. Achieving these goals will require both systemic reforms and innovative technologies that can bridge the gap between patients’ daily lives and the healthcare system.

    Monsenso is proud to contribute to this transformation. For example, through PhaseV, a national innovation programme supported by Innovation Fund Denmark, Monsenso provides the digital backbone for decentralised, real-world clinical studies, including within psychiatry. By enabling patients to share daily health data from home and giving clinicians access to these insights in real time, the project demonstrates how digital tools can strengthen early intervention, improve patient engagement, and extend care beyond traditional settings.

    Beyond Denmark, Monsenso also contributes at the European level through projects such as Personae (developing blended care models for mental health) and MentBest (creating digital tools to prevent common mental disorders). Together, these initiatives highlight how digital innovation can support more patient-centred, proactive, and sustainable mental health systems — both nationally and internationally.


    To learn more or explore a pilot or integration, book a demo or get in touch via our website.

     

    Mental health app could help prevent depression in young people at high risk

    Mental health app could help prevent depression in young people at high risk

    A cognitive behavioural therapy (CBT) app, based on Monsenso’s digital health platform, has been found to significantly prevent increases in depression in young people who are at high risk – and could be implemented as a cost- effective, large-scale public mental health measure.

    Globally, concern is growing about the high and steadily increasing rates of anxiety and depression in young people. Effective and scalable ways of preventing poor mental health in this group are needed, and digital tools such as mobile apps have been proposed as part of the solution.

    Whilst there is emerging evidence for mental health apps being effective in treating anxiety and depression, the EcoWeB project led by the University of Exeter is the first to rigorously test a mental health app on such a large scale across four countries. Two linked papers published on Oct 4 in Lancet Digital Health report the results of the ECoWeB-PREVENT and ECoWeB-PROMOTE trials, which ran concurrently in the four-year study funded by Horizon 2020. Critically, these studies found that a CBT self-help app based on Monsenso’s digital health platform can protect vulnerable young people against depression.

    Professor Ed Watkins from the University of Exeter led the project and said: “For young people with elevated risk, our findings suggest the CBT app does have a preventative effect on depression and could have a public health benefit. Participants’ quality-of-life measures were better, and their reported work and social functioning was better.

    “However, we also found that it’s hard to make improvements in young people who are basically doing okay. Our findings add to the evidence that prevention for depression works best when we identify and select individuals who are more at risk, rather than take a more universal approach. This identification could be done by an online self-screening process or through professional referral.”

    CEO Thomas Lethenborg at Monsenso said: “We are happy with the outcomes of this study and see great potential for our platform based on this. It shows that our platform can be used to deliver cost-effective guidance and interventions at scale and that it can be used to enable large-scale, international decentralised trials collecting continuous real-world data from participants.”

    The aim of the EUR 4-million project was to test the effects of mobile apps in preventing depression and promoting mental well-being for young people aged 16 to 22. In one of the largest studies of its kind, 3,700 young people took part across the UK, Germany, Belgium, and Spain and were allocated into two trials based on their emotional competence abilities at the start of the study. That resulted in 1,200 young people with reduced emotional competency scores that confer increased risk for depression such as increased worry and overthinking going into one trial focused on prevention, whilst 2,500 without such risk went into the other trial focused on wellbeing promotion.

    Those two groups were then randomised in equal numbers to three different apps developed by the project based on Monsenso’s platform. There was a self-monitoring app where people can report their emotions every day, a self-help app that provided personalised training in emotional competence skills, and a self-help app based on CBT principles. Participants were then followed up at three months and 12 months to see how their wellbeing and depression symptoms changed.

    The trials found the CBT app prevented an increase in depression, relative to self-monitoring in the higher risk sample, but that there was no difference between any of the interventions in their effects for the lower risk sample.

    Professor Ed Watkins at University of Exeter said: “Our results suggest that even when young people used the self-help app just a few times, there was a small but meaningful benefit. Because the app is scalable to large numbers of people in a cost-effective way, these effects have potential value as a public health intervention, within a broader portfolio of digital and in-person services and interventions. Next steps are to identify the active ingredients of the app that were beneficial and to improve engagement and ongoing use of these elements.”

    The project involved 13 different partners, including two commercial companies – digital health platform provider Monsenso and German voice analysis company audEERING. The University of Exeter (UK), LMU Munich (Germany), Ghent University (Belgium), and Universitat Jaume I (Spain), were the main treatment development and trial sites. Meanwhile, the University of Oxford led on the qualitative analysis.

    The studies are titled ‘Emotional competence self-help app versus cognitive-behavioural self-help app versus self-monitoring app to prevent depression in young adults with elevated risk (ECoWeB PREVENT): an international, multicentre, parallel, open-label, randomised controlled trial‘ and ‘Emotional competence self-help mobile phone app versus cognitive behavioural self-help app versus self-monitoring app to promote mental wellbeing in healthy young adults (ECoWeB PROMOTE): an international, multicentre, parallel, open-label, randomised controlled trial’, and both are published in Lancet Digital Health. This work was supported by European Union Horizon 2020 Personalised Medicine SC1-PM-07–2017 grant agreement 754657.


    Click the button below for more information about the Monsenso solution.

    Healthcare as a business case: Which importance is placed on societal impact vs economic impact?

    Healthcare as a business case: Which importance is placed on societal impact vs economic impact?

    Over the past decade, public spending on health in Denmark has been above the EU average. Due to the COVID-19 pandemic, government spending on healthcare has grown by more than 5% in 2020 alone [1], reaching total healthcare expenditures of DKK 270.794m in 2021 [2]. But how does Denmark decide which new treatment approaches to spend money on, and does the societal impact of healthcare measures play an equally important role as their economic impact?

    Though member states of the European Union are not precluded from “releasing marketing authorisations valid at national level” for new medicines/treatments, EU-wide marketing authorisations require new treatments to go through a centralised authorisation procedure managed by the European Medicines Agency (EMA), which evaluates the pharmaceutical quality, safety, and efficacy of new treatments [3]. However, whereas obtaining marketing authorisation on an EU level allows providers to offer their new medicines/treatments, it is mainly the national health authorities’ decisions on reimbursement and pricing measures that affect if patients will have access to them [3]. 

    In Denmark, the Danish Medicines Council (Medicinrådet) is an important body that assesses new treatment approaches and makes recommendations related to which medicines/treatments should be used in the Danish healthcare system [4]. Typically, cost-effectiveness and the impact on the healthcare budget are two important economic factors that national health authorities consider during such evaluations [3]. But what about the societal impact of new treatments? Does it receive sufficient consideration during the assessment procedures? 

    Let’s take innovative digital health solutions as an example. If we purely consider the direct economic costs digital health solutions for mental health can help to reduce, such as the costs for (re)hospitalisation (e.g., DKK 6.000 per day), do we really get a full picture of the value of these innovations in healthcare? Potentially not, as the societal impact would not have been considered.

    For instance, we would have not taken into account that digital health solutions for mental health can significantly improve the quality of life of individuals suffering from mental disorders [5], or that these innovations can enable mentally ill individuals to better recover and return to work faster. Neither would we have considered that digital solutions can facilitate making better use of resources available in the future, for instance by helping clinicians to handle growing patient data volumes they often feel overwhelmed with [6]. 

    The societal impact of new treatments may be more difficult to quantify than the pure health economic impact, but we believe it is an important factor to consider when evaluating innovative approaches. At Monsenso, we have made it our mission to enable better mental health for more people at lower costs, and the positive societal impacts and increased quality of life that we help generate are as important to us as the pure health economic impact.
    ——————————————————————————————————————————-
    About Monsenso
    Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and healthcare providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavors to deliver solutions that fit into the life of patients and healthcare professionals. To learn more visit  www.monsenso.com

    References: 

    [1] European Commission (2021). State of Health in the EU · Denmark · Country Health Profile 2021.
    https://eurohealthobservatory.who.int/docs/librariesprovider3/country-health-profiles/chp2021pdf/denmark-countryhealthprofile2021.pdf?sfvrsn=e79f1c55_7&download=true

    [2] Statistics Denmark (n.d.). Health care expenditure.
    https://www.dst.dk/en/Statistik/emner/oekonomi/offentlig-oekonomi/udgifter-til-sundhed

    [3] European Parliament (2015). Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines.
    https://www.europarl.europa.eu/RegData/etudes/STUD/2015/542219/IPOL_STU(2015)542219_EN.pdf

    [4] Medicinrådet (n.d.). Danish Medicines Council.
    https://medicinraadet.dk/om-os/in-english

    [5] Monsenso (2022). Key research findings.
    https://www.monsenso.com/wp-content/uploads/2022/06/Monsenso-Key-Research-Findings.pdf

    [6] Elsevier Health (2022). Clinician of the Future Report 2022.
    https://www.elsevier.com/connect/clinician-of-the-future